Clinical Trial

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-09-10; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2021-12-13
Trial Details
NCT Number NCT05051436
Lead Sponsor Philip Kern
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Pre-diabetes, Obesity
Enrollment 96 participants
Start Date 2021-12-13
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-03